Rotavirus G2P antigen (RV G2P)

The Rotavirus G2P antigen refers to the primary surface proteins of the G2P[4] rotavirus strain, specifically the VP7 glycoprotein (G-type) and the VP4 protease-sensitive protein (P-type). These proteins are the critical targets for the host's neutralizing antibody response and are essential for the virus's ability to attach to and penetrate host enterocytes in the small intestine (PubMed: 29153080). The G2P[4] genotype is one of the most common causes of severe rotavirus gastroenteritis worldwide, characterized by acute watery diarrhea, vomiting, and dehydration in infants and young children (CDC: Rotavirus). In the context of pharmacology, these antigens are utilized in both monovalent and multivalent live-attenuated vaccines, such as RotaTeq (which includes the G2 component) and Rotarix (which provides cross-protection against G2P[4]), to elicit protective immunity (NIH: StatPearls). Therapeutic development also explores monoclonal antibodies and recombinant subunit vaccines targeting these specific epitopes to provide broader protection against emerging G2P variants. Monitoring the prevalence of G2P antigens is vital for assessing vaccine efficacy and understanding the molecular epidemiology of rotavirus outbreaks (WHO: Rotavirus Surveillance).

Other names

Rotavirus G2P[4] antigenRotavirus VP7 G2 and VP4 P[4] proteinsG2P[4] Rotavirus surface proteinsRotavirus Serotype G2 Protease-sensitive type P[4]

Vaccines containing these antigens induce the production of neutralizing antibodies (IgA and IgG) that target the VP7 (G-type) and VP4 (P-type) proteins, preventing viral attachment and entry into intestinal epithelial cells (enterocytes) during subsequent exposures.